Why Influencers Use the FDA to Bash Research Peptides

The FDA approves drugs. That much is true. But the way it approves drugs, and who pays for that process, changes everything about what that approval actually means.

Here is the full chain first, because without it, none of the specific details make sense.

A pharmaceutical company develops a drug. That company then pays the FDA to review it. If the FDA approves it, the company profits. When FDA officials finish their careers at the agency, the majority go to work for those same companies. And those companies spend hundreds of millions of dollars every year lobbying the government to shape the rules that govern all of this. That is the system. Now we can zoom in.

The mechanism that makes this all work has a name: PDUFA, the Prescription Drug User Fee Act, which is the law that allows pharmaceutical companies to directly fund the FDA's drug review process. As of fiscal year 2024, a single application for drug review costs a pharmaceutical company $4,198,000 in fees. These fees now make up approximately 65% of the entire budget that the FDA's drug review division runs on. The companies being regulated are the ones paying for the regulation.

This creates a structural problem that has nothing to do with individual corruption and everything to do with incentives. When your operating budget depends on the fees paid by the companies whose products you approve, you are not independent of those companies. You are funded by them.

The relationship does not end when the drug gets approved.

A 2018 analysis published in Science looked at FDA medical officers who left the agency between 2006 and 2019 and found that 62% of them went directly to work for the pharmaceutical industry. Scott Gottlieb, who served as FDA Commissioner from 2017 to 2019, joined Pfizer's board of directors the same year he left. This is sometimes called regulatory capture, which is when the industry being regulated gains enough influence over the regulatory body that the regulator begins serving industry interests rather than public ones.

And the lobbying reinforces the whole structure. The pharmaceutical and health products industry spent $374 million on federal lobbying in 2023, which made it the single highest-spending lobbying sector in the country. That spending translates to roughly 1,500 to 1,800 registered lobbyists working the federal government at any given time, or about three lobbyists for every single member of Congress.

This is the system. Now here is why it matters for peptides specifically.

Research peptides are compounds built from naturally occurring amino acid sequences that the body already produces or recognizes. Because they are derived from natural sequences, they cannot be patented. And because they cannot be patented, no pharmaceutical company can own exclusive rights to sell them after approval. A company that spends nearly a billion dollars navigating the approval process, the median capitalized cost to bring a new drug to market between 2009 and 2018 was approximately $985 million according to a 2020 analysis in JAMA Internal Medicine, needs to recoup that investment through protected profits. If a competitor can manufacture the same compound the day after approval and sell it cheaper, that investment never pays off.

So no company will ever pay $4 million just to have a peptide reviewed, let alone the full development cost, because there is no business model on the other side. The absence of FDA approval for research peptides is not a signal that they are dangerous. It is a signal that they are not profitable to approve.

This is where the argument that "FDA unapproved means unsafe" breaks down completely, because the approval process itself is not a neutral scientific evaluation of safety and efficacy. It is a commercial transaction that only gets completed when there is a profitable reason to complete it.

Now consider the compounding pharmacy angle, because it is worth understanding mechanically.

Compounding pharmacies operate under a different regulatory framework than manufacturers of approved drugs. They can legally produce peptides and dispense them with a prescription, which gives the product a layer of pharmaceutical legitimacy without requiring the same approval pathway. This means a person or business selling compounded peptides can point to a licensed pharmacy, point to a prescription requirement, and market themselves as the responsible, regulated option, while simultaneously arguing that research chemical suppliers operating outside that framework are dangerous.

The argument sounds like a safety argument. It is actually a market positioning argument.

The honest version of the compounding pharmacy case is that there are real quality control advantages to a licensed compounding operation over an unverified chemical supplier, and that is worth acknowledging. Purity verification, sterility, and accurate dosing matter, and a legitimate compounding pharmacy with proper oversight addresses those concerns in ways that a random peptide vendor may not. That part of the argument has substance.

What does not have substance is invoking FDA approval as the standard when the entire approval architecture exists to serve patentable pharmaceutical products and will never be applied to naturally occurring peptide sequences for purely economic reasons.

Using a captured regulatory system as your authority when it benefits your business, while positioning yourself as outside the mainstream and skeptical of institutions when that framing also benefits your business, is not a coherent position. It is two different marketing strategies wearing the same face.

The FDA stamp does not tell you whether something works or whether it is safe. It tells you whether a company found it profitable enough to pay nearly a billion dollars to find out. Those are not the same thing, and treating them as the same thing is either confused or dishonest.

---

References

1. FDA PDUFA Fee Schedule — Federal Register (published annually). FY 2024 application fee: $4,198,000.
2. FDA Budget Justification to Congress — PDUFA user fees fund approximately 65% of CDER/CBER human drug review budget.
3. Piller, C. (2018). "Is FDA's revolving door open too wide?" Science. Found 62% of FDA medical officers who left between 2006-2019 went to work for pharmaceutical industry.
4. OpenSecrets.org — Center for Responsive Politics. Pharmaceutical/health products industry spent $374 million on federal lobbying in 2023, #1 ranked industry. Approximately 1,500-1,800 registered lobbyists (roughly 3:1 ratio to members of Congress).
5. Scott Gottlieb served as FDA Commissioner 2017-2019, joined Pfizer board of directors in 2019.
6. Wouters, O.J., McKee, M., Luyten, J. (2020). "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." JAMA Internal Medicine. Median capitalized cost: $985 million per drug.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness